1. Open-label therapy with alirocumab in patients with heterozygous familial hypercholesterolemia: Results from three years of treatment 
Robert Dufour, Jean Bergeron, Daniel Gaudet, Robert Weiss, G. Kees Hovingh, Zhizhi Qing, Feng Yang, Matthew Andisik, Albert Torri, Robert Pordy, Daniel A. Gipe 
International Journal of Cardiology 
Volume 228, Pages (February 2017)
DOI: /j.ijcard
Copyright © 2016 Swiss Tropical and Public Health Institute Terms and Conditions

2. Fig. 1 Patient disposition.
AE, adverse event, HeFH, heterozygous familial hypercholesterolemia, OLT, open-label treatment, Q2W, every 2weeks, Q4W, every 4weeks.
International Journal of Cardiology  , DOI: ( /j.ijcard )
Copyright © 2016 Swiss Tropical and Public Health Institute Terms and Conditions

3. Fig. 2
Absolute LDL-C levels over time and achievement of (A) risk-based LDL-C goals and (B) LDL-C percentage change from baseline.
International Journal of Cardiology  , DOI: ( /j.ijcard )
Copyright © 2016 Swiss Tropical and Public Health Institute Terms and Conditions

4. Fig. 3
Levels of other lipids and lipoproteins over time: (A) apo B, (B) non-HDL-C, (C) Lp(a), (D) HDL-C, and (E) triglycerides.
Values shown on the charts are rounded to one decimal place.
International Journal of Cardiology  , DOI: ( /j.ijcard )
Copyright © 2016 Swiss Tropical and Public Health Institute Terms and Conditions